Your GP runs 12 markers. I run 65, quarterly. Here's why.

The standard Norwegian fastlege panel runs around twelve markers. Total cholesterol, LDL, HDL, triglycerides, glucose, HbA1c, a complete blood count, maybe a TSH if you ask. Once a year, if you remember to book it.

That setup answers one question: am I currently sick. It does not answer the question that actually matters for an active man in his thirties or forties. Am I on the right trajectory.

Twelve markers, annually, is the floor of medicine. Sixty-five markers, quarterly, is the floor of optimization. This post is the spine of what the second one looks like, and what to ask your lab for if you want to run it.

Key takeaways:

• Standard reference ranges are designed to flag disease, not optimize health. The gap between "normal" and "optimal" is where most active 30 to 45 year olds actually live.
• A quarterly cadence (12 to 16 weeks) is the smallest unit of biology that responds to a behavioral or supplemental intervention. Annual testing gives you no trajectory.
• Six systems anchor a comprehensive quarterly panel: lipid sub-panel, inflammation, metabolic, hormones, thyroid full, and micronutrients. Each runs in the low hundreds of NOK at a private Norwegian lab.
• The 2024 National Lipid Association consensus puts ApoB targets at under 90 mg/dL for intermediate risk and under 60 mg/dL for very high risk. Fasting insulin optimal sits at 2 to 5 μIU/mL, where the standard alert threshold is 24.9.

Your annual panel measures whether you are sick. The quarterly panel measures whether you are optimizing.

The Norwegian primary-care lipid panel has barely changed in twenty years. Total cholesterol, LDL, HDL, triglycerides, glucose, HbA1c, a full blood count, sometimes TSH and creatinine. The panel works for what it was designed to do: catch obvious disease in a general population on a low-cost schedule.

It misses three things an active 35-year-old actually needs.

It misses particle count versus cholesterol mass. LDL is the proxy. ApoB is the count. One big LDL particle and ten small ones can carry the same cholesterol mass; the ten are far more atherogenic. I covered that fully in ApoB vs LDL: what your doctor is testing wrong.

It misses early metabolic dysfunction. HbA1c is a 90-day glucose average and lags actual insulin resistance by years. Fasting insulin and HOMA-IR catch it earlier.

And it misses the trajectory. One reading, once a year, tells you almost nothing about whether what you are doing is moving the number. The biology that responds to a behavior change moves on a 12 to 16 week timescale. That is the unit of feedback you actually need to iterate.

The 65-marker spine, across six systems

The spine I run quarterly groups into six functional systems. Each system has a small set of markers that earn their place; everything else is an optional add-on by quarter.

• Lipid sub-panel. ApoB, Lp(a), oxidized LDL, plus the standard four (LDL, HDL, triglycerides, total cholesterol). Lp(a) is genetically fixed and only needs to be measured once, but the rest move with diet, exercise, and time.
• Inflammation. hsCRP, IL-6, homocysteine, fibrinogen. hsCRP is the most sensitive marker of low-grade chronic inflammation. Homocysteine doubles as a B12 and folate sufficiency check.
• Metabolic. HbA1c, fasting insulin, fasting glucose, HOMA-IR (calculated from glucose × insulin). An OGTT once a year is the right stress test if you want to push the system.
• Hormones, men. Free testosterone, total testosterone, SHBG, DHEA-S, AM cortisol, estradiol. Free T over total T because it represents bioactive hormone; Attia's longevity panel always tests SHBG alongside so the free-T number means something.
• Thyroid, full. TSH, free T3, free T4, reverse T3, anti-TPO. A standalone TSH misses subclinical hypothyroidism and the reverse T3 patterns that show up in over-trained athletes.
• Micronutrients and critical extras. 25-OH vitamin D, B12, ferritin, RBC magnesium, zinc, RBC folate. Plus a comprehensive metabolic panel (ALT, AST, ALP, GGT, creatinine, eGFR, BUN) and a complete blood count with differential.

That stack is sixty-something markers depending on how you count the OGTT and CMP sub-items. The exact number is not the point. The point is six systems, each with a small set of markers, run together as a panel so the data triangulates.

Why quarterly, and not annual

The argument for quarterly testing is not biohacker maximalism. It is feedback-loop math.

Most useful biological interventions, whether dietary, supplemental, training-based, or pharmacological, show up in blood markers on a 8 to 16 week timescale. A 12-week Zone 2 cardio program produces measurable VO2 max change. A lipid response to dietary fat changes typically shows in 8 to 12 weeks. A protocol change in supplementation tends to take 12 weeks before the bloodwork reflects it.

That window is the unit of feedback.

If you test annually, you get one data point per year. You cannot tell whether the protocol change you made in month three drove the change you see in month twelve, or whether the holiday eating block in month nine masked it. Annual testing gives you a number. It does not give you a trajectory.

Quarterly testing gives you four data points per year. Each one is a check against the protocol you ran during the prior quarter. The biology is short enough that the link between behavior and result is still legible, not lost in 11 months of other inputs.

After four quarters, you do not have one annual snapshot. You have a year of decision-grade data. That is the difference between guessing and iterating.

Optimal vs. normal: the gap that matters most

Standard clinical reference ranges are not designed to define optimal. They are designed to flag disease. The lab algorithm asks "is this person sick?" not "is this person on the trajectory they want?"

The gap between those two questions is wide.

• Fasting insulin. Standard reference ranges flag hyperinsulinemia above 24.9 μIU/mL. The longevity-medicine optimal range sits at 2 to 5 μIU/mL. Mortality data on fasting insulin under 5 shows significantly lower cardiovascular and all-cause mortality. The clinical "normal" is three to five times higher than what the data suggests is actually optimal.
• ApoB. The standard "normal" range tops out around 100 to 130 mg/dL. The 2024 National Lipid Association consensus stratifies targets: under 90 for intermediate risk, under 70 for high risk, under 60 for very high risk. Attia's public target is under 60 with under 40 as aspirational. A reading of 95 will get green-checked by your fastlege; longevity medicine considers that suboptimal for any active 35-year-old who wants to be moving the number down, not parking it.
• Homocysteine. Standard lab flag at above 15 μmol/L. The optimal target is under 10 μmol/L, with under 8 cited for longevity. Higher homocysteine is associated with elevated cardiovascular and stroke risk in graded fashion. A reading of 12 looks "normal" but is well into the zone where B-vitamin intervention pays off.

That is three markers. The same pattern repeats across the panel. The reading the lab calls normal is not necessarily what an active operator wants to optimize toward.

This is also why a standard panel can give you false reassurance. Your LDL can be mid-range while your ApoB is flagged. Your fasting glucose can be 5.2 while your fasting insulin is 12 and you are already insulin-resistant. The standard panel will say green. The fuller panel says yellow.

What this actually looks like in Norway

The mechanics of running this cadence in Norway are the practical question most readers actually have. The honest answer is that the system was not built for it.

Your fastlege issues lab requisitions when you give them a clinical reason. Norwegian primary care orders tests to investigate symptoms, not to track quarterly trajectories in asymptomatic 35-year-olds. If you walk in healthy and ask for a 65-marker panel, the default answer is no.

The lab itself is Fürst. They run essentially everything on the spine: advanced lipid sub-panels (ApoB, Lp(a)), full hormone panels, micronutrients, the lot. The bottleneck has never been the assay. It has been the requisition.

Two practical paths exist for asymptomatic operators:

• A private clinic that issues the order. Aleris, Volvat, or a longevity-focused private GP can write the requisition to Fürst on your behalf. Workable per quarter, but adds an appointment fee and friction on top of the lab cost.
• A platform that owns the requisition and the analysis. This is the gap I co-founded Humn to fill. It is the only Norwegian platform where I can run this panel quarterly without routing every cycle through a GP visit. The 65-marker cadence I describe in this post is the panel I run through it. Currently in stealth, soft launch later in 2026.

Private route pricing stacks individual markers and small panels. The full quarterly cadence described above runs in the low four-figure NOK range per quarter, with Lp(a) and the one-off genetic markers as costs you only pay once.

The pattern is straightforward once the access problem is solved. Run the panel every 12 to 16 weeks. Time the draw to match your protocol cycles so the data lands when you need to make the next decision. Treat each result as a check on the prior quarter, not as a snapshot.

What 16 months of quarterly testing taught me

I have run a version of this panel quarterly for the last 16 months. The decision-grade data it produces is what makes the cadence worth it.

The headline arc is the lipid one. December 2024 baseline: ApoB 1.2 g/L, LDL 4.7 mmol/L. Q1 2026: ApoB 0.95 g/L, LDL 2.79 mmol/L. A 21 percent drop on ApoB and a 41 percent drop on LDL across 16 months, no statin. The protocol moves that produced it are covered in the ApoB vs LDL post. The protocol was tested, adjusted, retested because the quarterly panel made the relationship between behavior and result legible quarter by quarter.

That is the actual operator value of quarterly testing. It is not the markers themselves. It is the feedback loop.

The same loop discipline applies anywhere you want to iterate on yourself instead of guess. It is the same point I made about building rather than studying when learning AI. Specific numbers, repeated cadence, no ceremony. The number is the input. The protocol is the output. The retest tells you whether the protocol was right.

The annual panel catches disease. The quarterly panel gives you a feedback loop. They are not the same product, and the people running the second one are not optimizing for the same thing the first one was designed to detect.

Your fastlege runs twelve markers, annually, because they are looking for trouble. Run sixty-five, quarterly, because you are looking for a trajectory.